Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

Investigational Site Number 1240004, Barrie

Investigational Site Number 1240006, Brampton

Investigational Site Number 1240002, Brampton

Investigational Site Number 1240005, Burlington

Investigational Site Number 1240003, Calgary

Investigational Site Number 1240024, Chicoutimi

Investigational Site Number 1240014, Concord

Investigational Site Number 1240017, Etobicoke

Investigational Site Number 1240030, Greenfield Park

Investigational Site Number 1240031, Halifax

Investigational Site Number 1240026, Hamilton

Investigational Site Number 1240011, Laval

Investigational Site Number 1240016, London

Investigational Site Number 1240015, London

Investigational Site Number 1240019, Mirabel

Investigational Site Number 1240018, Montreal

Investigational Site Number 1240023, Montreal

Investigational Site Number 1240020, Montreal

Investigational Site Number 1240029, Montreal

Investigational Site Number 1240027, Nepan

Investigational Site Number 1240025, Newmarket

Investigational Site Number 1240013, Saint-Marc-des-Carrieres

Investigational Site Number 1240021, Oakville

Investigational Site Number 1240009, Oshawa

Investigational Site Number 1240008, Québec

Investigational Site Number 1240022, Québec

Investigational Site Number 1240028, Saint-Lambert

Investigational Site Number 1240033, Toronto

Investigational Site Number 1240001, Toronto

Investigational Site Number 1240012, Vancouver

Investigational Site Number 1240007, Victoriaville

Investigational Site Number 1240032, Winnipeg